The ineffectiveness of the Chinese Communist pneumonia (COVID-19) vaccine developed and produced in China has caused international concern. Some British virus experts have recently pointed out that the Chinese vaccine is not really effective against the COVID-19 virus, and some medical professionals have even suggested that mass vaccination with the ineffective Chinese vaccine could give rise to a variant of the virus.
The Daily Mail recently reported that Chile’s pneumonia epidemic has worsened after a mass vaccination with the Chinese vaccine, citing medical experts who say that Chile’s recent increase rather than decrease in diagnosis rates is a warning to the world that even with a successful mass vaccination program, the Chinese vaccine is too ineffective. Even with a successful mass vaccination program, the vaccine made in China is too ineffective to stop the spread of the virus.
The report cites comments by Ian Jones, a virologist at the University of Reading in the United Kingdom, who noted that “[Chinese] vaccines are being produced very quickly, but they contain viral proteins that are not relevant to protection and, in fact, a large part of what you get when you get vaccinated is wasted.”
Jones said that the CCP pneumonia vaccines developed in China are inactivated vaccines, which lack specificity and cause the body’s immune system to release many antibodies when injected into the body, but these antibodies do not actually help people fight the real CCP pneumonia virus.
None of the four vaccines approved for use by the Chinese government have yet been placed on the World Health Organization’s emergency use list, and Chinese vaccine manufacturers have not released complete Phase III clinical trial data for their vaccines. However, dozens of developing countries have ordered Chinese vaccines and begun mass vaccinations, including Brazil and Chile, where the epidemic is severe, due to underdeveloped economies and related technologies.
According to the data, Chile has ordered 60 million doses of the Coxin vaccine. Forty percent of the country’s population has now been vaccinated against the Chinese communist virus, the vast majority of them with the Coxin vaccine. However, the number of confirmed cases in Chile has continued to soar since mid-February, leading to a renewed blockade in more than 80 percent of the country. According to recent data released by the University of Chile, after the first dose of the Coxin vaccine, the effectiveness of protection was only 3%, and after the second dose two weeks later, the effectiveness of protection only rose to 56.5%.
In contrast, the Pfizer and Modena vaccines in the United States were 95% and 94% effective, respectively, and even the British AstraZeneca vaccine, which can cause rare cases of blood clots, was 79% effective.
The Daily Mail also reported that at least 53 countries around the world have purchased the Chinese-made Chinese Communist pneumonia vaccine, most of them developing countries in South America, Africa and Southeast Asia, which lack special storage facilities and have opted for the inexpensive and easily stored Chinese vaccine.
The Voice of America also reported on Friday (16) that the Chinese government is pushing for a domestic vaccine with only about 50-79 percent protection, and one medical source confessed that he is worried that the Chinese vaccine is so ineffective that mass vaccination could give rise to a variant of the virus that could become a future global epidemic buster.
In fact, the Chinese Communist Party authorities are not only forcing a mass vaccination program within China, but are also actively exporting their domestic vaccines to nearly 70 countries. More recently, the Chinese government has also offered “visa facilitation” as a bait-and-switch for foreigners who need to enter China for business or official duties to receive Chinese vaccines.
The Voice of America commented that the Chinese government’s “visa facilitation” policy is a great incentive for business people who must travel frequently to and from China, but it also puts some business people in the dilemma of “money or life.
Recent Comments